FDA Offers Advice On Using Patient Reports For Trial Endpoints
This article was originally published in The Gray Sheet
Executive Summary
FDA will support the use of patient-reported data in clinical trials as long as the sponsor makes the measurement tools as robust and meaningful as possible, the agency indicates in a Feb. 3 draft guidance document to industry
You may also be interested in...
Neurotechnology Needs Better Outcome Measures, Diagnostics – VC Investors
The development and regulatory approval of new drugs and devices for treating diseases of the brain is hindered by the inadequacy of existing diagnostics and outcome measures, according to venture capitalists who spoke at a recent neurotech industry forum
Neurotechnology Needs Better Outcome Measures, Diagnostics – VC Investors
The development and regulatory approval of new drugs and devices for treating diseases of the brain is hindered by the inadequacy of existing diagnostics and outcome measures, according to venture capitalists who spoke at a recent neurotech industry forum
AdvaMed Asks For Pre-Review Option For Patient-Reported Outcome Tools
AdvaMed is urging FDA to pre-review sponsors' strategies for using patient-reported data to support product labeling claims before a clinical trial is initiated